Video

ecancer's extensive video archive features interviews, panel discussions and conference coverage on almost every topic in oncology.
Spotlight on global cancer control at ASCO 2022
Prof Eduardo Cazap - Editor-in-Chief, ecancer and SLACOM
Spotlight on global cancer control at ASCO 2022 ( Prof Eduardo Cazap - Editor-in-Chief, ecancer and SLACOM )
10 Jun 2022
UICC announces global coalition to increase access to essential cancer medicines...
Dr Cary Adams - Chief Executive Officer, Union for International Cancer Control
UICC announces global coalition to increase access to essential cancer medicines in low and lower middle-income countries ( Dr Cary Adams - Chief Executive Officer, Union for International Cancer Control )
9 Jun 2022
Comment: LUMINA results show that women with low levels of the Ki67 biomarker ca...
Dr Corey Wayne Speers - University of Michigan, Ann Arbor, USA
Comment: LUMINA results show that women with low levels of the Ki67 biomarker can avoid outcomes related to radiotherapy ( Dr Corey Wayne Speers - University of Michigan, Ann Arbor, USA )
9 Jun 2022
Biomarker guidance allows patients 55 or older with low-grade luminal A-type bre...
Dr Timothy J. Whelan - McMaster University, Ontario, Canada
Biomarker guidance allows patients 55 or older with low-grade luminal A-type breast cancer to avoid radiation therapy ( Dr Timothy J. Whelan - McMaster University, Ontario, Canada )
9 Jun 2022
Momelotinib superior to danazol in symptomatic and anaemic myelofibrosis patient...
Dr Ruben A. Mesa - UT Health San Antonio MD Anderson Cancer Center, San Antonio,...
Momelotinib superior to danazol in symptomatic and anaemic myelofibrosis patients previously treated with a JAK inhibitor ( Dr Ruben A. Mesa - UT Health San Antonio MD Anderson Cancer Center, San Antonio, USA )
7 Jun 2022
Biomarker analysis of the NeoALTTO trial provides oncofertility insight for youn...
Dr Matteo Lambertini - San Martino Hospital, Genoa, Italy
Biomarker analysis of the NeoALTTO trial provides oncofertility insight for younger breast cancer patients ( Dr Matteo Lambertini - San Martino Hospital, Genoa, Italy )
6 Jun 2022
Pembrolizumab demonstrates clinically meaningful improvement in distant metastas...
Dr Georgina Long - The University of Sydney, Sydney, Australia
Pembrolizumab demonstrates clinically meaningful improvement in distant metastasis-free survival in patients with melanoma ( Dr Georgina Long - The University of Sydney, Sydney, Australia )
6 Jun 2022
Elacestrant significantly prolongs PFS for ER+/HER2- metastatic breast cancer wi...
Dr Virginia G. Kaklamani - UT Health San Antonio MD Anderson Cancer Center, San ...
Elacestrant significantly prolongs PFS for ER+/HER2- metastatic breast cancer without prior chemotherapy patients ( Dr Virginia G. Kaklamani - UT Health San Antonio MD Anderson Cancer Center, San Antonio, USA )
6 Jun 2022
ASCO 2022: Breast cancer highlights
Dr Matteo Lambertini - San Martino Hospital, Genoa, Italy
ASCO 2022: Breast cancer highlights ( Dr Matteo Lambertini - San Martino Hospital, Genoa, Italy )
6 Jun 2022
Neoadjuvant ipilimumab and nivolumab immunotherapy could become new standard of...
Dr Christian U. Blank - The Netherlands Cancer Institute, Amsterdam, Netherlands
Neoadjuvant ipilimumab and nivolumab  immunotherapy could become new standard of care for resectable stage III melanoma ( Dr Christian U. Blank - The Netherlands Cancer Institute, Amsterdam, Netherlands )
6 Jun 2022
Updated data from the Phase 1/2 MajesTEC-1 study evaluating teclistamab, a BCMA ...
Dr Ajay Nooka - Winship Cancer Institute of Emory University, Georgia, USA
Updated data from the Phase 1/2 MajesTEC-1 study evaluating teclistamab, a BCMA x CD3 bispecific antibody ( Dr Ajay Nooka - Winship Cancer Institute of Emory University, Georgia, USA )
6 Jun 2022
CheckMate 9ER: aRCC patients on nivolumab plus cabozantinib achieved deeper resp...
Dr Cristina Suarez - Vall d’Hebron University Hospital, Catalonia, Spain
CheckMate 9ER: aRCC patients on nivolumab plus cabozantinib achieved deeper responses vs sunitinib ( Dr Cristina Suarez - Vall d’Hebron University Hospital, Catalonia, Spain )
6 Jun 2022